NES
AUXL

New England Securities’s AUXILIUM PHARAMCEUTICALS INC AUXL Stock Holding History

New England Securities’s Portfolio AUXL Stock Details AUXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-282
Closed -$6K – 1895
2013
Q4 		$6K Buy
+282
New +$5.32K ﹤0.01% 1189

Other funds holding AUXL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TCP
TAMRO Capital Partners Alexandria, Virginia $369M AUM 1.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

New England Securities's AUXL Position: Q1 2014 in Review

New England Securities sold out of AUXILIUM PHARAMCEUTICALS INC (AUXL) in Q1 2014, closing a stake of 282 shares — an estimated $6K sold.

New England Securities first reported a position in AUXL in Q4 2013 and held it in 1 quarter. The position peaked at $6K in Q4 2013. 163 funds tracked by Wall St. Rank hold AUXL as of Q1 2014.

  • New England Securities reported no remaining AUXILIUM PHARAMCEUTICALS INC position as of Q1 2014 after selling out during the quarter.
  • New England Securities sold 282 AUXILIUM PHARAMCEUTICALS INC shares in Q1 2014, an estimated $6K.
  • New England Securities first reported a position in AUXILIUM PHARAMCEUTICALS INC in Q4 2013 and held it in 1 quarter.
  • New England Securities's AUXILIUM PHARAMCEUTICALS INC position peaked at $6K in Q4 2013.
  • 163 funds tracked by Wall St. Rank held AUXILIUM PHARAMCEUTICALS INC as of Q1 2014.

Based on New England Securities's 13F filing for Q1 2014, filed 30 Apr 2014.